This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of nasopharyngeal administration of 13.6% high-concentration 35 kDa hyaluronan (HA35) care gel in subjects with chronic rhinitis and chronic pharyngitis. Eligible participants will receive the study gel twice daily for 10 consecutive days. The primary objectives are to assess rapid changes in nasopharyngeal discomfort, posterior pharyngeal discomfort, and nasal obstruction within 30 minutes after the first administration. Secondary objectives include evaluation of overall symptom improvement at day 10, changes in subjective mental clarity, and safety and tolerability throughout the treatment period. This is a minimal-risk, non-pharmacological supportive care intervention.
Age 18-80 years, male or female
Clinically diagnosed with chronic rhinitis and chronic pharyngitis for ≥3 months
Baseline nasopharyngeal discomfort NRS score ≥4 points
Baseline posterior pharyngeal discomfort NRS score ≥4 points
Acute upper respiratory tract infection within 2 weeks
Use of antihistamines, intranasal corticosteroids, decongestants, or other nasal medications within 2 weeks prior to screening
History of nasal/sinus surgery within 6 months
Known hypersensitivity to hyaluronan or any gel ingredients
Single group
13.6% High-Concentration 35 kDa Hyaluronan (HA35) Nasopharyngeal Care Gel
DeviceA topical, non-pharmacological nasopharyngeal care gel containing 13.6% high-concentration 35 kDa hyaluronan. It is designed to support mucosal hydration and reduce inflammation in the nasopharynx. Administration is via direct nasopharyngeal application, twice daily for 10 consecutive days.
Change in Posterior Pharyngeal Discomfort and Cough NRS Score (0-10)
Change in posterior pharyngeal discomfort and associated cough intensity, measured using a 0-10 Numeric Rating Scale (NRS), where 0 = no discomfort/cough and 10 = worst imaginable discomfort/cough.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
